| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $6,653,598 ) (Continued on the next page) |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 001 | 4 | NIH | 1/23/2026 | $350,562 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA266921 | SESORRS endoscopy for the staging and evaluation of colorectal cancer | 000 | 5 | NIH | 1/9/2026 | $224,099 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99GM154065 | Towards a structural understanding of transcriptional regulation by ZMYM2-KDM1A-CoREST | 000 | 2 | NIH | 1/14/2026 | $125,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284254 | Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma | 000 | 4 | NIH | 1/13/2026 | $92,813 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35GM157235 | Molecular mechanisms of DNA double strand break repair by homologous recombination | 000 | 2 | NIH | 1/12/2026 | $400,500 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA269990 | Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | 000 | 4 | NIH | 1/16/2026 | $413,593 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA286345 | In vivo testing of an agonistic anti-GITR mAb that induces cell surface clustering to augment signal transduction and a 2nd Gen bispecific anti-GITR/PD1 Ab derivative for improved anti-tumor activity | 000 | 2 | NIH | 2/6/2026 | $187,399 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA296230 | Targeting the CDK4/6 pathway in MiT/TFE-translocation renal cell carcinoma | 000 | 2 | NIH | 1/7/2026 | $187,204 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL171973 | Molecular mechanisms of splicing dependency in cohesin-mutant myelodysplasia | 000 | 3 | NIH | 2/9/2026 | $445,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA296618 | Exploiting a Novel DNA Repair Defect in Ewing Sarcoma | 000 | 2 | NIH | 12/5/2025 | $470,964 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA155010 | Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | 000 | 15 | NIH | 1/27/2026 | $683,283 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA221874 | Comprehensive minimal residual disease tracking in cancer | 000 | 6 | NIH | 12/15/2025 | $398,378 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279414 | Variability in Opioid Prescribing Across the Cancer Care Continuum: A Multi-Level Analysis | 000 | 3 | NIH | 1/16/2026 | $644,180 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 000 | 3 | NIH | 1/15/2026 | $654,298 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276268 | Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer | 000 | 4 | NIH | 1/26/2026 | $505,595 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 002 | 4 | NIH | 1/30/2026 | $8,991 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG075837 | Contribution of a novel OPN-producing CD11c+ microglial subset to AD | 000 | 3 | NIH | 1/7/2026 | $455,377 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA266194 | Selective disruption of histone deacetylase complexes using protein interaction modulators | 000 | 5 | NIH | 1/8/2026 | $612,114 |
| | 2026 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA251470 | Yoga for Chemotherapy-induced Peripheral Neuropathy Treatment (YCT) Trial | 000 | 6 | NIH | 2/10/2026 | $0 |
| | 2026 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA283154 | Targeting mitochondrial vulnerabilities to drive intrinsic melanoma immunogenicity | 000 | 2 | NIH | 11/19/2025 | $0 |
| | 2026 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA286805 | Dissecting the Role of Germline Genetics in RAS-Driven Cancers | 000 | 2 | NIH | 12/23/2025 | $0 |
| | 2026 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K01DK132455 | The Role of Mitochondrial TNAP in Adaptive Thermogenesis | 000 | 3 | NIH | 1/30/2026 | -$57,196 |
| | 2026 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U24HG004059 | Bioconductor: An Open-Source, Open-Development Computing Resource for Genomics | 000 | 21 | NIH | 1/21/2026 | $0 |
| | 2026 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA288665 | Impact of preanalytical conditions on functional cancer biomarkers | 001 | 2 | NIH | 1/29/2026 | $406,351 |
| | 2026 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA286537 | Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas | 000 | 2 | NIH | 2/9/2026 | $0 |
| | 2026 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35CA242427 | Reading mitochondrial apoptotic signaling to identify active cancer therapeutics | 000 | 7 | NIH | 11/14/2025 | $0 |
| | 2026 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA276156 | Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies | 000 | 3 | NIH | 1/8/2026 | $0 |
| | 2026 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA251555 | Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approaches | 000 | 5 | NIH | 2/5/2026 | $0 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P50CA240243 | Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant | 000 | 5 | NIH | 1/6/2026 | -$163,942 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA245209 | Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid Leukemia | 000 | 5 | NIH | 1/12/2026 | $0 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32DK132864 | Elucidating novel molecular mechanisms of irisin-mediated effects via integrin | 000 | 3 | NIH | 1/29/2026 | -$12,631 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32GM149115 | Evaluating the mechanism by which the DYNLL1-MRE11 complex regulates DNA end resection and genome stability. | 000 | 2 | NIH | 1/27/2026 | -$13,197 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA294507 | Myeloma multidimensional precancer atlas | 000 | 1 | NIH | 1/22/2026 | $0 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA246648 | A web-based patient-reported symptom monitoring and self-management portal for adolescent and young adult breast cancer survivors | 000 | 3 | NIH | 12/22/2025 | -$1,056 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA246648 | A web-based patient-reported symptom monitoring and self-management portal for adolescent and young adult breast cancer survivors | 000 | 3 | NIH | 12/22/2025 | -$3,299 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | T32CA136432 | Research Training in Pediatric Oncology | 000 | 15 | NIH | 11/21/2025 | -$210,218 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35CA220497 | Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance | 000 | 7 | NIH | 1/30/2026 | -$41,777 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01GM136859 | NMR Fingerprinting: Leveraging optimal control pulse design, tailored isotope labeling, and machine learning to study intractable proteins | 000 | 5 | NIH | 1/21/2026 | $0 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK124115 | Mitochondria mediated intercellular metabolic coupling in bone marrow regeneration | 000 | 4 | NIH | 11/20/2025 | $0 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA272982 | Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers | 000 | 3 | NIH | 1/16/2026 | $0 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA272657 | Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer | 000 | 3 | NIH | 1/16/2026 | $0 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA248910 | Scaling up tobacco control in India: Comparing smartphone to in-person training for implementing an evidence-based intervention to reduce tobacco use among schoolteachers | 000 | 4 | NIH | 12/9/2025 | $0 |
| | 2026 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA240816 | Characterizing the LINE-1 Retrotransposition-Replication Conflict | 000 | 5 | NIH | 11/25/2025 | $0 |
| | 2026 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P50CA168504 | Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer | 000 | 10 | NIH | 11/21/2025 | $0 |
| | 2026 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P50CA127003 | Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer | 000 | 15 | NIH | 1/2/2026 | -$47,371 |
| | 2026 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P01CA229092 | Immune Modulation After Allogeneic HCT | 001 | 5 | NIH | 2/10/2026 | -$245 |
| | 2026 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P01CA229092 | Immune Modulation After Allogeneic HCT | 000 | 5 | NIH | 12/8/2025 | $0 |
| | 2026 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35GM131802 | Data Analysis Tools for Emerging High-Throughput Technologies | 000 | 5 | NIH | 2/11/2026 | $0 |
| | 2026 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA263838 | Leveraging mHealth to deliver integrated pain-CBT, opioid monitoring, and self-management support for advanced cancer patients coping with chronic pain | 000 | 3 | NIH | 1/8/2026 | -$1 |
|
